Actinium says ATNM-400 beats approved androgen receptor inhibitors in resistant prostate cancer models at SNMMI 2026

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM

0.00
  • Actinium Pharmaceuticals presented new preclinical data on ATNM-400 at the SNMMI 2026 annual meeting on June 2, 2026.
  • Studies showed ATNM-400 stayed active in prostate cancer models that no longer responded to leading androgen receptor inhibitors.
  • Monotherapy delivered strong tumor control; combinations with standard hormone drugs produced durable complete responses in resistant disease.
  • Dosing appeared flexible with a consistent tolerability profile, supporting multiple potential regimens as the program moves toward clinical testing.
  • Comparisons suggested competitive activity versus PSMA-targeted radiotherapies, with a lower expected risk of salivary gland toxicity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606030725PR_NEWS_USPR_____NY74604) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.